HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.

Ryan Shea Ying Cong TanWhee Sze OngKyung-Hun LeeAbner Herbert LimSeri ParkYeon Hee ParkChing-Hung LinYen-Shen LuMakiko OnoTakayuki UenoYoichi NaitoTatsuya OnishiGeok-Hoon LimSu-Ming TanHan-Byoel LeeHan Suk RyuWonshik HanVeronique Kiak Mien TanFuh-Yong WongSeock-Ah ImPuay Hoon TanJason Yongsheng ChanYoon Sim Yap

Published in: BMC medicine (2022)

HER2-low BC had a superior prognosis compared to HER2-zero BC in the non-metastatic setting, though absolute differences were modest and driven by HER2 IHC 1+ BC. ERBB2 CNV merits further investigation in HER2-negative BC.

Keyphrases

copy number
metastatic breast cancer
mitochondrial dna
genome wide
squamous cell carcinoma
dna methylation
tyrosine kinase
randomized controlled trial
binding protein
gene expression
cross sectional
long non coding rna